Delivery Order SPE2DB20D1004-SPE2DB23FF3P6
Award Date
3/3/23
Potential Completion Date
3/6/23
Potential Value
$7.7K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $15,985.25 contract is a firm fixed-price delivery order for HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a vaccine product. The award has an ultimate completion date of November 21, 2024. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a vaccine product. The award has a ceiling value of $126,372.00 and is a firm fixed price delivery order contract, with a period of performance through January 7, 2025. The contract is not designated as a set-aside. AmerisourceBergen also holds a...
This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine, with a ceiling value of $1,684.96 and a completion date of March 4, 2025. The contract is a Delivery Order under the DLA's Indefinite Delivery Contract (IDC) with AmerisourceBergen, valued at $999,999,999 and running through...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine, with a ceiling value of $2,446.86 and a period of performance through November 25, 2024. The contract is a Delivery Order issued under an Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of the global pharmaceutical distribution company AmerisourceBergen Corporation. The contract, valued at $3,595.57, is for the provision of the HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML vaccine. The delivery order falls under a larger indefinite delivery contract (IDC) awarded by DLA to AmerisourceBergen Drug Corp, valued at up to $999,999,999.00 through December 31,...
This federal contract award, valued at $30,656.80, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a vaccine product, with a completion date of September 19, 2023. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop...
This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of the major pharmaceutical distribution company Amerisourcebergen Corporation, is for the provision of the HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML vaccine to the Defense Logistics Agency (DLA). The $1,577.28 fixed-price delivery order contract has a completion date of May 22, 2024. This award is associated with Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,212.40 firm fixed-price delivery order is for HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a vaccine product. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range...
The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order contract worth $6,309.12 to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a vaccine product, with a period of performance through November 4, 2024. This contract is a child task order under AmerisourceBergen's larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,212.40, is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a vaccine product. The contract is a delivery order, with a firm fixed price pricing type, and an ultimate completion date of March 21, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA...